Press Releases

06.10.2015

Pfizer Builds Upon Robust Body Of Knowledge For XELJANZ® (tofacitinib citrate) With Clinical Trial And Real-World Use Data At The European League Against Rheumatism Annual Congress (EULAR 2015)

06.08.2015

Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology

06.04.2015

Get Ready. Get Set. Get Old. Pfizer Challenges Conventional Views of Aging Through New Campaign

05.30.2015

Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

05.29.2015

Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

05.28.2015

Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer

05.28.2015

Pfizer Global Survey Finds Adults with Rheumatoid Arthritis Who Feel Comfortable Speaking Up About Their Concerns Have a More Positive View of Their Health

05.19.2015

Pfizer Invites Public to View and Listen to Webcast of June 2 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

05.14.2015

Pfizer Receives Request For Additional Information From FTC Regarding Proposed Acquisition Of Hospira

05.14.2015

Bar Ilan University to work with Pfizer Inc. to evaluate drug delivery via DNA Nanorobots

05.14.2015

Marc Tessier-Lavigne, Ph.D. to Leave Pfizer Board of Directors

05.13.2015

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody